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Background
Prospective data on neonatal outcome following in utero
exposure to antirerovirals (ARVs) are essential compo-
nents of safety monitoring of these life-saving therapies.
Toward this end, APR was created in 1989 and is now one
of the largest ongoing pregnancy registries in the world.
Methods
APR is an international registry that uses a prospective
exposure-registration cohort design to monitor potential
birth defects following in utero ARV exposure. Health care
providers voluntarily enroll exposed pregnant women,
then provide follow-up neonatal data. We analyzed APR
data for their ability to detect, at 80% power with Type I
error rate of 5%, potential increases in birth defect preva-
lence following fetal 1st trimester (TRI) exposure (when
organogenesis occurs), vs. 2nd and 3rd TRI exposures.
Summary of results
By January 2008, APR received 11,209 prospective
reports. Of these, 9,400 live birth (LB) outcomes were
available, including 3,951 LB following 1st TRI exposures.
These reports allow detection of a potential 1.5-fold
increase in overall anomalies following 1st TRI exposure
to any ARV compared to 2nd/3rd TRI exposures. We
found no such increase. Birth defect prevalence after any
1st TRI ARV exposure was 3.0% vs. 2.6% following any
2nd/3rd TRI ARV exposure (1.13 relative risk, 95% CI =
0.89, 1.43). Twelve individual drugs have >200 1st TRI
reports and allow us to detect a potential 1.5–2-fold
increase in all defects for each agent (Table 1). Such an
increase has not been found.
Two drugs met the threshold for evaluation and further
monitoring: zidovudine was associated with an increased
risk of hypospadius [1], and a higher than expected defect
prevalence following didanosine exposure that has no
apparent pattern and is not statistically significant [2].
Conclusion
In summary, prospectively collected APR data have not
detected an overall increase in birth defects following in
utero ARV exposure during organogenesis. We continue to
follow two trends that do not reach statistical significance.
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Defects LB Prevalence (95%CI)
Zidovudine 87/2808 3.1% (2.5%,3.8%)
Lamivudine 85/2784 3.1% (2.4%,3.8%)
Nelfinavir 33/972 3.4% (2.3%,4.7%)
Nevirapine 18/737 2.4% (1.5%,3.8%)
Stavudine 19/651 2.9% (1.8%,4.5%)
Ritonavir 16/628 2.5% (1.5%,4.1%)
Abacavir 17/512 3.3% (1.9%,5.3%)
Tenofovir 11/491 2.2% (1.1%,4.0%)
Efavirenz 10/364 2.7% (1.3%,5.0%)
Didanosine 16/353 4.5% (2.6%,7.3%)
Lopinavir 6/328 1.8% (0.7%,3.9%)
Indinavir 6/272 2.2% (0.8%,4.7%)Page 2 of 2
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